Strategic area of application
Human Medicine
Application market
Cardiology - Immune, AutoIm & Inflam. diseases - Infectiology - Parasitology - Neurological diseases - Oncology - Pneumology
Activities
Therapeutics, Pharma or Biotech - Medical device
Technologies
Design & Modelling studies - Vaccine - Antibodies - Protein - Peptide - Others
Presentation of company's activity
Cynbiose is a specialty preclinical CRO offering research services with a core expertise and focus on the non-human primate (NHP) model. Our company is unique in Europe.
Our preclinical offer covers:
- Exploratory pharmacokinetics, central PK and pharmacodynamics studies
- Early safety studies, toxicokinetics and biodistribution studies
- Efficacy studies (PoC) in multiple therapeutic areas such as infectious and respiratory diseases, Central Nervous System, immune and inflammation disorders.
Our subsidiary, Cynbiose Respiratory, is a preclinical CRO specializing in respiratory diseases and aerosol therapies.
R&D is an important part of our business. Indeed, we are involved in several collaborative research projects with leading academic research teams and biopharmas, to develop new preclinical models and support progress in biomedical science.
Cynbiose also launched CYNBIOME, the 1st preclinical excellence network on microbiota and infectious diseases based on the Non-Human Primate (NHP) model.
Key features of company
- Our facility is AAALAC accredited since 2015 and we can operate studies from BSL 1 to 3. We have also developed unique capabilities in performing studies with ATMPs such as gene therapies containing GMOs (viral vectors, …).
- We provide hybrid exploratory designs, customized & high value-added services in a high quality-based GLP-like environment.
- Scientific expertise and support, Innovative models, Flexibility and Reactivity, R&D mindset, Customer relationship
Skills and know-how
- Customized solutions for lead generation, lead optimization and preclinical development of drug candidates based on a translational model.
- Innovative NHP efficacy models and use of translational technologies (cerebral and lung microdialysis, functional imaging (PET, MRI, …) , telemetry, video-monitoring, …).
- In-depth expertise for the preclinical assessment of therapeutic candidates targeting the central nervous system: central pharmacokinetics, cerebral microdialysis, neutotoxicity.
Higlights
Clinically relevant in vivo non-human primate model for exploratory pharmacokinetics, pharmacodynamics, early safety and efficacy models.
Pharmacological models for Proof of Concept studies: cardiovascular and neurovascular diseases, inflammatory diseases, infectious diseases, respiratory diseases and metabolic diseases, rheumatology.
Our scientific team is able to set-up on-demand and customized efficacy models through R&D programs.
Product pipeline 1
Therapeutic area: Efficacy model in Neurovascular diseases
Preclinical: Middle Cerebral Artery Occlusion (MCAO) non-human primate model
Product pipeline 2
Therapeutic area: Efficacy models in infectious and respiratory diseases
Preclinical: - hRSV, hMPV - SARS-CoV-2 model - Other bacterial and viral infectious models available: more information on our website. CYNBIOME: the 1st preclinical excellence network on microbiota and infectious diseases based on the NHP model.
Product pipeline 3
Therapeutic area: Efficacy model in inflammatory diseases
Preclinical: A non-human primate model of multiple sclerosis, psoriasis, DTH, skin graft
